Trends in pharmaceutical targeting of clinical indications: 1930–2013
作者： Michael S. Kinch , Janie Merkel , Sheila Umlauf
DOI: 10.1016/J.DRUDIS.2014.05.021
关键词:
摘要: An analysis of FDA-approved new molecular entities (NMEs) reveals trends in therapeutic applications. Four groupings (infectious diseases, cardiovascular autoimmune/inflammatory diseases and cancer) capture more than 60% NMEs. Infectious are the most targeted indications. Near turn millennium, rate approvals for infectious decreased. The absolute relative number NMEs targeting psychiatric, neurological pain/itch indications also declined. By contrast, cancer have risen past two decades as orphan These results suggest drug development community has largely been responsive to public health market needs. However, finite resources might indicate emphasis on some unmet needs could come at cost others.
elsevier.com
sci-hub.se 参考文章(5)
Manning Feinleib, National Center for Health Statistics (NCHS) Encyclopedia of Biostatistics. ,(2005) , 10.1002/0470011815.B2A16042
Michael S. Kinch, The rise (and decline?) of biotechnology Drug Discovery Today. ,vol. 19, pp. 1686- 1690 ,(2014) , 10.1016/J.DRUDIS.2014.04.006
Michael S. Kinch, Austin Haynesworth, Sarah L. Kinch, Denton Hoyer, An overview of FDA-approved new molecular entities: 1827–2013 Drug Discovery Today. ,vol. 19, pp. 1033- 1039 ,(2014) , 10.1016/J.DRUDIS.2014.03.018
K I Kaitin, J A DiMasi, Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 Clinical Pharmacology & Therapeutics. ,vol. 89, pp. 183- 188 ,(2011) , 10.1038/CLPT.2010.286
Olivier Wellman-Labadie, Youwen Zhou, The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? Health Policy. ,vol. 95, pp. 216- 228 ,(2010) , 10.1016/J.HEALTHPOL.2009.12.001